TMCnet News
Outpost Medicine Expands Senior Leadership TeamOutpost Medicine, a biopharmaceutical company focused on the development of new treatments of urologic and gynecologic diseases and disorders, today announced additions to its senior leadership team, including:
"Following our recent $41 million Series A financing and licensing of our lead product candidate, OP-233, from Takeda, we are very pleased to announce the formation of the Outpost senior leadership team," said David Socks, Chief Executive Officer of Outpost. "Gale, Gordon, Mike, and Nancy are proven leaders with deep urology and drug development expertise ideally suited to accelerate the development of OP-233 and grow Outpost into a leading urology and women's health therapeutics company." OP-233 (formerly TAK-233) is a clinical-stage product candidate in development for the treatment of stress urinary incontinence. Dr. Martin most recently served as Vice President, Clinical Development Biosimilars at Pfizer, which she joined through the acquisition of Hospira, where she substantially built out the clinical development organization. Prior to Hospira, she spent six years with Astellas Pharma in roles of increasing responsibility, most recently as Senior Medical Director, Scientific and Medical Affairs, with a focus on the urology therapeutic area. During her tenure at Astellas, Dr. Martin led the clinical development of mirabegron through Phase II, III, and global regulatory approvals for the treatment of overactive bladder. She also led the medical affairs team through product launch. Previously, Dr. Martin held roles in clinical pharmacology at Aventis and Hoffman (News - Alert)-La Roche. She earned her M.D. from the University of Medicine and Dentistry of New Jersey and Pharm.D. from the University of Illinois at Chicago.
Ms. Kennedy most recently served as Senior Director, Clinical Science at Takeda. During that time, she had clinical leadership responsibilities for multiple clinical-stage urology programs, including OP-233 (formerly TAK-233). Prior to Takeda, Ms. Kennedy was Programme Director at Plethora Solutions, where she led Phase III development for a sexual dysfunction program. Earlier in her career, she held roles of increasing responsibility in clinical pharmacology and clinical development at Ono Pharmaceutical, AstraZeneca, and Sanofi. Ms. Kennedy holds a B.Sc. in Biochemistry and Pharmacology from the University of Strathclyde. Mr. Ramsay joined Outpost from The Medicines Company, which he joined through the acquisition of Incline Therapeutics, where he was Senior Vice President, Manufacturing and Supply Operations. Prior to Incline, he was Senior Vice President, Manufacturing Operations at Cell Genesys (News - Alert) with responsibility for three GMP manufacturing facilities. Previously, Mr. Ramsay served as Vice President, Transdermal Manufacturing at ALZA Corporation. He has also held various positions with SEQUUS Pharmaceuticals, including Vice President, Manufacturing Operations, as well as various positions at Syntex Corporation focusing on manufacturing, product development, and regulatory affairs. Mr. Ramsay holds a Bachelor of Pharmacy degree from the University of Nottingham. About Outpost Medicine Outpost Medicine is a biopharmaceutical company focused on the development of novel therapeutics for the treatment of urologic and gynecologic disorders. Its lead product candidate, OP-233 (formerly TAK-233), is currently in Phase I for the treatment of stress urinary incontinence (SUI). SUI occurs when physical movement or activity, such as coughing, sneezing, laughing, exercise, or heavy lifting puts pressure (physical stress) on weakened urethral sphincter or pelvic floor muscles resulting in unintentional loss of urine. SUI is distinct from urge incontinence, also known as overactive bladder (OAB), which is caused by involuntary contraction of bladder muscles. In the United States alone, more than 18 million women are afflicted with SUI. There are currently no medicines approved in the United States to treat this condition, and approved agents in other parts of the world tend to be poorly tolerated or have limited efficacy. Located in Boston and London, Outpost is a private company launched in 2016 with a $41 million Series A venture capital financing from Frazier Healthcare Partners, Adams Street Partners, Novo A/S, and Vivo Capital. For more information, visit Outpost's website at www.outpostmedicine.com. View source version on businesswire.com: http://www.businesswire.com/news/home/20160718005289/en/ |
